HACKENSACK, N.J., May 1, 2018 /PRNewswire/ -- Champions
Oncology, Inc. (Nasdaq: CSBR), engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs, today announced that
Amy Wesa, Ph.D, has joined the
company as Director of Immuno-Oncology Research.
Ronnie Morris, CEO of Champions
Oncology commented, "The appointment of Dr. Wesa demonstrates our
long-term commitment to help pharmaceutical companies make better
decisions as they develop immunotherapeutics. Immuno-oncology
represents a fast growing part of the oncology drug pipeline. With
more than 1,000 ongoing immune-oncology clinical trials, there is a
need for better in-vivo and in-vitro models and tools to guide and
support the efficient development of this new class of
therapeutics. We believe we are well positioned to support these
efforts, especially with the appointment of Dr. Wesa. In this
new role for the organization, Dr. Wesa will lead immune-oncology
research and development, working across the organization to expand
Champion's immune-oncology portfolio of services and research
efforts."
Dr. Wesa brings more than 15 years of experience in
translational immuno-oncology, with expertise in the development of
cell and gene therapy, including CAR T cells, as well as other
therapeutics for solid and hematologic malignancies. Most recently,
Dr. Wesa was the Associate Director of ImmunoOncology at Intrexon
Corporation. Prior to that, she was the Director of Research and
Development at Celsense, Inc. While a Tenure-Track Assistant
Professor of Dermatology and Immunology at the University of Pittsburgh, Dr. Wesa was selected as
an American Cancer Society Research Scholar before embarking on her
career in industry. Dr. Wesa completed her postdoctoral fellowship
at the University of Pittsburgh Cancer
Institute. She earned her Ph.D. in Cancer Biology from Wayne State University School of Medicine in
Detroit and her B.S. in Biology
from the University of Michigan in Ann
Arbor.
About Champions Oncology, Inc.
Champions Oncology,
Inc. is engaged in the development of advanced technology solutions
and services to personalize the development and use of oncology
drugs. The Company's TumorGraft technology platform is a novel
approach to personalizing cancer care based upon the implantation
of primary human tumors in immune deficient mice followed by
propagation of the resulting engraftments, or TumorGrafts, in a
manner that preserves the biological characteristics of the
original human tumor in order to determine the efficacy of a
treatment regimen. The Company uses this technology in
conjunction with related services to offer solutions for two
customer groups: Personalized Oncology Solutions, in which
results help guide the development of personalized treatment plans,
and Translational Oncology Solutions, in which pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development can lower the cost and increase the speed of developing
new drugs. TumorGrafts are procured through agreements with a
number of institutions in the U.S. and overseas as well as through
Champions' Personalized Oncology Solutions business. For more
information, please visit www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-adds-amy-wesa-phd-as-director-of-immuno-oncology-research-300639327.html
SOURCE Champions Oncology, Inc.